It is estimated that one in five people in Northern Ireland are living with a chronic pain condition like arthritis, ...

FDA reviews TNX-102 SL for Fibromyalgia by August 2025, with no advisory required. See why we recommend a buy on TNXP stock.

Some forms of exercise training and pharmacological-based interventions may improve fibromyalgia-related sleep disturbances, though evidence is limited.

Tonix Pharmaceuticals shares are trading higher by 22.5% during Monday's session. The company announced that the FDA will not ...

New research has identified cannabis-derived terpenes—compounds that give plants their distinctive aroma—as effective ...

Terpenes from the Cannabis sativa plant may be a viable medication for fibromyalgia and post-surgical pain relief, according ...

Tonix Pharma (TNXP) has submitted an NDA for its candidate TNX-102 SL for fibromyalgia, with a PDUFA date set for August 15, 2025. See why I'm on the sidelines.

Terpenes from cannabis may relieve chronic pain without THC’s psychoactive effects. Researchers found that certain terpenes ...

Tonix Pharmaceuticals (TNXP) announced that the U.S. Food and Drug Administration will not require an Advisory Committee meeting to discuss the ...

The FDA previously granted Fast Track designation to TNX-102 SL for the management of fibromyalgia in 2024, a designation intended to expedite FDA review of important new drugs to treat serious ...

August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new ...